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Abstract
The management of heart failure has changed significantly over the last 30 years, leading to improvements in the quality of life
and outcomes, at least for patients with a substantially reduced left ventricular ejection fraction (HFrEF). This has been made
possible by the identification of various pathways leading to the development and progression of heart failure, which have been
successfully targeted with effective therapies. Meanwhile, many other potential targets of treatment have been identified, and the
list is constantly expanding. In this review, we summarise planned and ongoing trials exploring the potential benefit, or harm, of
old and new pharmacological interventions that might offer further improvements in treatment for those with HFrEF and extend
success to the treatment of patients with heart failure with preserved left ventricular ejection fraction (HFpEF) and other heart
failure phenotypes.
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Introduction
Heart failure and its management have changed dramatically
over the last 30 years. In the 1980s, patients were included in
clinical trials of heart failure based purely on the clinical opin-
ion of the investigator with no objective criteria to confirm the
diagnosis. The patients were younger and had fewer comor-
bidities but a broad range of left ventricular ejection fraction
(LVEF) comparedwith contemporary trials; quality of life was
often poor and mortality rate high. Fluid retention, causing
peripheral oedema and breathlessness, was the main therapeu-
tic target. Digoxin and diuretics were the only available med-
ical treatments, sometimes accompanied with bed rest and
fluid restriction.
Subsequently, objective criteria such as LVEF and, more
recently, natriuretic peptides were required to select patients
for trials. Initially, trials targeted vasoconstriction, using ni-
trates and hydralazine [1], and pathologically activated
neuro-hormonal systems, using angiotensin-converting en-
zyme (ACE) inhibitors, angiotensin II receptor blockers
(ARBs), beta-blockers and mineralocorticoid antagonists
(MRAs). These trials provided evidence that, for heart failure
with reduced LVEF (HFrEF), treatment could improve ven-
tricular function, symptoms and signs, as well as morbidity
and mortality [2–5]. More recently, other targets and novel
treatments have been identified for HFrEF. Ivabradine, an
agent that slows the rate of sinus node discharge and therefore
heart rate, improved ventricular function, symptoms and mor-
bidity for patients who do not achieve a heart rate < 70 bpm on
a beta-blocker; for those with a heart rate > 75 bpm or who
were not treated with a beta-blocker, mortality was also re-
duced [6, 7]. Patients with HFrEF in sinus rhythm with a QRS
du r a t i o n > 130 mse c b en e f i t t e d f r om c a r d i a c
resynchronization therapy (CRT) [8, 9] with improvements
in cardiac function, symptoms, morbidity and mortality.
Patients who were at low risk of dying for any reason other
than an arrhythmia benefitted from an implantable
cardioverter-defibrillator (ICD) although its utility is currently
being called into question [10, 11]. The development of ded-
icated specialist HF teams has also been of great importance to
inform patients of their diagnosis, prognosis and need for
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therapy, to improve the implementation of and adherence to
treatment and to facilitate titration of medications to target
doses, all of which leads to greater patient-satisfaction and
better long-term outcomes [12].
Despite these successes, the ‘war’ on heart failure is far
from won. For patients hospitalised with worsening heart fail-
ure aged less than 75 years, mortality at 1 year may be as high
as 20% and up to 40% in those aged > 85 years [13]. For
patients with stable HFrEF who survive the initial 6 months
after diagnosis and are enrolled in contemporary clinical trials,
the annual risk of the composite of hospitalisation for heart
failure or mortality is about 10% [14]. Outcome amongst pa-
tients who do not participate in clinical trials is much worse
[15]. Older patients and those with a recent episode of decom-
pensation despite guideline-recommended therapy who re-
quire intensification of therapy have a much worse prognosis.
Disappointingly, many patients do not receive, and therefore
cannot benefit from, guideline-recommended therapy [16,
17].
More appropriate use of investigations and less complex
diagnostic algorithms are likely to reveal that there are many
undiagnosed cases of heart failure in the community, particu-
larly with preserved left ventricular (LV) ejection fraction
(HFpEF) [18], a condition for which some insist no effective
therapy exists as yet, although treatment with a thiazide di-
uretic and ACE inhibitor exerted remarkable benefits in the
HYVET trial in a group of patients many of whom undoubt-
edly had undeclared HFpEF [19]. Of note, the European
Society of Cardiology (ESC) heart failure registry suggested
little difference in the therapies applied to patients with HFrEF
and HFpEF in clinical practice; perhaps clinicians are some-
times wiser than the guidelines they are asked to follow [20].
The age-adjusted incidence of heart failure may be fairly
stable but the total number of patients who will develop heart
failure will rise substantially in the next few decades as the
proportion of people aged > 60 years increases [21].
Nowadays, many people survive the onset of cardiovascular
disease for long periods. Treatment of hypertension, diabetes,
chronic kidney disease, atrial fibrillation and ischaemic heart
disease might delay the onset of heart failure, but procrastina-
tion is not the same as prevention. It is likely that most people
with cardiovascular disease will develop heart failure before
they die [22, 23]. Strategies to diagnose and treat heart failure
before it becomes clinically overt require much more research
investment [24]. An increased awareness of what is important
to older people may identify novel outcomes and treatments
and define the future role of palliative care and euthanasia.
Enormous amounts of routinely collected personal health
records, biochemical and imaging data are now available for
novel analytical approaches such as machine-learning and ar-
tificial intelligence that will identify novel pathways leading to
heart failure and redefine its epidemiology in the next decade
(Fig. 1). The definition as well as management of heart failure
might be transformed, with care and services personalised to
the individual patient’s needs.
Currently, there are many ongoing trials exploring the po-
tential for benefit, or harm, of old and new treatments that
might improve the management of HF: summarising novel
pharmacological interventions is the purpose of this review;
space precludes an in-depth review of devices (electrical, me-
chanical or valve) or biological interventions (other than in-
fluenza vaccination) although key trials are shown in the
Table 1 (and in supplementary Table 1, if they aim to enrol
fewer than 200 patients).
Neuro-endocrine interventions
Augmentation of natriuretic and other peptides:
sacubitril/valsartan
One of the key therapeutic successes for heart failure has been
the inhibition of neuro-endocrine pathways with ACE-Is,
ARBs, MRAs and beta-blockers. Recently, a new class of
agents, angiotensin receptor neprilysin inhibitors (ARNI),
has proved superior to ACE-Is for the treatment of HFrEF
[14]. Neprilysin inhibitors retard the degradation ofmany pep-
tides, including atrial (ANP) and B-type natriuretic peptides
(BNP) and vasoactive intestinal polypeptide, which have di-
uretic, vasodilator and inotropic properties [25, 26]. In the
Comparison of Sacubitril–Valsartan versus Enalapril on
Effect on NT-proBNP in Patients Stabilized from an Acute
Heart Failure Episode (PIONEER-HF) trial, initiation of
sacubitril/valsartan for patients with either new-onset or
chronic HFrEF (n = 881) during the in-hospital recovery
phase after an acute decompensation was as safe as initiating
enalapril, but led to a greater, and earlier (within 1 week),
reduction in plasma concentrations of NT-proBNP, which
was sustained until the end of 8 weeks follow-up [27]. A
reduction in a composite of serious HF-related adverse clinical
events was also observed [28]. However, about 20% of sur-
viving patients discontinued treatment with either ACEi or
ARNI and only 55% achieved guideline-recommended doses
of the ARNI [27]. In the PRIME trial (n = 118), patients with
HF, an LVEF < 50% and functional mitral regurgitation (MR)
who were randomised to sacubitril/valsartan had a greater re-
duction in the effective regurgitant orifice area (EROA) com-
pared with valsartan alone at 12 months follow-up [29]. Other
trials are currently ongoing in specific populations with
HFrEF, inc lud ing those wi th symptoms a t res t
(NCT02816736), or an elevated pulmonary artery pressure
(NCT02788656) or in Japan (NCT02468232).
The Prospective Comparison of ARNI with ARB Global
Outcomes in HF With Preserved Ejection Fraction
(PARAGON; NCT01920711) is a randomised, double-blind,
event-driven trial comparing the efficacy and safety of
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valsartan vs sacubitril/valsartan in patients with HFpEF that
has enrolled 4822 patients (mean age 73 ± 8 years, median
NT-proBNP 911 (interquartile range 464–1610) pg/mL, > 2/
3 in sinus rhythm) [30]. The results should be reported later in
2019. PARALLAX (NCT03066804) is another large (> 2,000
patients) randomised, double-blind trial of patients with
HFpEF, comparing sacubitril/valsartan with a control group
(the investigator can chose whether this is an ACE-I, an ARB
or neither, in which case patients assigned to the control group
receive placebo); the effect on plasma NT-proBNP and exer-
cise capacity after 24 weeks of treatment and safety are the
main outcomes of interest.
Concerns exist that the inhibition of neprilysin could inter-
fere with breakdown of beta amyloid (βA) peptides, which
might accumulate in the brain and contribute to the develop-
ment of Alzheimer’s disease. The PERSPECTIVE trial
(NCT02884206) is currently recruiting ~ 500 patients with
HF and LVEF > 40%, to investigate whether chronic admin-
istration of sacubitril/valsartan for 3 years leads to a decline in
cognitive function when compared with valsartan alone.
Management of hyperkalaemia: patiromer
and sodium zirconium cyclosilicate
Currently, based on the evidence provided by clinical trials,
guidelines recommend that ACEi, ARB and MRA should not
be initiated if serum potassium is > 5.0 mmol/L (5.2 mmol/L
for ARNI) and that doses should be reduced or treatment
stopped if serum potassium is > 5.5 mmol/L. Accordingly,
many patients with HFrEF do not receive guideline-
recommended doses of these agents [16, 17, 31]. Older pa-
tients, those with type-2 diabetes mellitus and those with renal
dysfunction are more likely to develop hyperkalaemia [32].
Patients who fail to achieve guideline-recommended doses of
these medications due to hyperkalaemia have a worse prog-
nosis, but this may be because of concomitant renal dysfunc-
tion or hypotension.
Patiromer and sodium zirconium cyclosilicate are novel
oral treatments that bind potassium in the gastrointestinal
(GI) tract and rapidly normalise serum potassium concentra-
tions. Whether their use will allow doctors to prescribe and
patients to achieve guideline-recommended doses of RAASi
more often and whether this will improve outcomes are now
being investigated. Results of substantial trials are not expect-
ed before 2021.
Vasodilators: vericiguat and nitroxyl
Nitric oxide (NO) activates soluble guanylate cyclase (sGC),
causing an elevation of intracellular cyclic guanosine
monophosphate (cGMP) in vascular and non-vascular tissues,
such as the myocardium and kidney. In heart failure, produc-
tion of NO is reduced and its degradation is increased, leading
to an increase in systemic and pulmonary arteriolar and ve-
nous tone, thereby increasing the after-load and pre-load on
the failing myocardium [33]. Vericiguat is an oral sGC
Fig. 1 The present and future of heart failure. Conventionally, the
prevalence of heart failure is thought to be about 1.5% in the adult
population. However, it might be substantially greater than that, as
many cases remain undiagnosed, particularly amongst older people, and
are usually only identified when symptoms are severe enough to require
hospital admission. Several ongoing trials target different pathways that
might contribute to disease progression. Success provides tentative
insights into the likely mechanisms of progression, although off-target
effects may lead to serendipitous effects (this is probably true of most
effective treatments for heart failure). There may be many reasons for
failure other than the lack of importance of the targeted mechanism.
This may include a smaller than anticipated benefit with consequent lack
of power, lack of target engagement, a mechanism that is important but
only works in a specific subgroup (e.g., heart rate reduction in sinus
rhythm) or one that is overwhelmed by competing risks (e.g., rivaroxaban
2.5 mg bd for advanced heart failure in sinus rhythm). Processing large
volumes of routinely collected electronic health records using novel an-
alytical approaches, such as artificial intelligence and machine learning,
will provide new insights into disease classification, mechanisms of pro-
gression and therapeutic targets. Epidemiology, definition and manage-
ment of heart failure are likely to be transformed in the next decade, with
care and services matched to the individual patient’s needs in a “preci-
sion-medicine” approach
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stimulator which increases cGMP production. Phase 2 trials
showed that vericiguat is well tolerated in patients with HFrEF
[34]. A large (~ 4,500 patients) phase 3 trial (VICTORIA;
NCT02861534) is currently evaluating whether vericiguat im-
proves morbidity and mortality compared with placebo in pa-
tients with chronic HFrEF [35].
Nitroxyl is a second-generation donor of nitric oxide that
causes vasodilatation and may have inotropic effects, which
are only partially mediated by an increase in cGMP [36]. A
phase 2 trial (STAND-UP; NCT03016325) is currently eval-
uating the safety and efficacy (changes in NT-proBNP and
symptoms) of 48-h infusion of nitroxyl in 310 patients admit-
ted with decompensated HFrEF. Smaller mechanistic trials are
investigating its effects on cardiac and renal function.
Inotropic agents
Omecamtiv mecarbil, levosimendan, digoxin
and recombinant human neuregulin-1
Omecamtiv mecarbil (OM) is a cardiac myosin activator that
alters the kinetics of actin/myosin cross-bridges, prolonging
the duration of the systole and, thus, stroke volume, without
increasing ATP consumption [37]. Phase II trials showed that
IV administration of OM in patients with acutely decompen-
sated HFrEF had the expected haemodynamic effects but no
clear clinical benefit [38]. In The Chronic Oral Study of
Myosin Activation to Increase Contractility in Heart Failure
(COSMIC-HF) trial, oral OM given for 20weekswas safe and
reduced LV size and plasma concentrations of NT-proBNP
levels; the latter effect persisted for 4 weeks after treatment
withdrawal suggesting that long-term favourable structural
remodelling had occurred [39]. The Phase II trial programme
has repeatedly shown small increases in serum troponin con-
centrations, raising concerns about safety that, so far, appears
unfounded. Increases in troponin appear unrelated to any clin-
ical evidence of myocardial ischaemia or adverse outcomes. A
large (n ~ 8,000) phase III trial of patients with chronic HFrEF
(with 25% planned to be enrolled during a hospitalisation for
an episode of decompensation) is nearing completion of en-
rolment and should report in 2021 (GALACTIC-HF;
NCT02929329).
Levosimendan, a vasodilator and calcium sensitiser, has
been used to treat refractory HF in many countries despite
two large neutral trials conducted in patients with acute HF
and a large trial of an oral formulation in patients with chronic
severe HF that showed reductions in NT-proBNP and an im-
provement in QoL but did not otherwise improve outcome
[40, 41]. Recently, small trials have explored the effects of
giving levosimendan intermittently to patients with chronic
severe HFrEF and shown that this can reduce plasma concen-
trations of NT-proBNP [42]. Larger trials are now attempting
to determine whether this strategy can improve symptoms,
exercise capacity, morbidity and mortality in patients with
HFrEF.
Neuregulin-1 proteins are important for the development
and function of cardiac myocytes. Small phase II studies re-
ported that recombinant human neuregulin-1 improved
haemodynamics and promoted reverse LV remodelling in pa-
tients with HFrEF [43, 44]. A phase III study is currently
testing whether, compared to placebo, use of daily (for
10 days) IV infusions, followed by weekly boluses, of recom-
binant human neuregulin-1 is feasible, safe and effective in
reducing mortality in Chinese patients with mild to moderate
chronic HFrEF.
Digoxin may be the oldest medicine still prescribed for
heart failure, but controversies persist about its benefits. In
the DIG trial, conducted before many current HF treatments
were available, digoxin did not reduce mortality compared
to placebo, although it did reduce HF hospitalisations by
28%. A retrospective analysis suggested that patients with
serum concentrations of digoxin of 0.5–0.9 ng/mL were
more likely to benefit [45, 46]. A prospective, randomised,
placebo-controlled trial is testing whether lower doses of
digoxin, guided by measurements of its plasma concentra-
tions (0.5–0.9 ng/mL), will reduce HF hospitalisations and
cardiovascular death in ~ 1,000 symptomatic patients with
chronic HF and a reduced or mid-range LVEF (< 50%)
(NCT03783429).
Congestion
Congestion is an important cause of the symptoms and signs
of HF, leads to adverse atrial and ventricular remodelling,
arrhythmias and worsening renal function and is associated
with poor outcomes [47, 48]. Controlling congestion is a
key therapeutic goal in the management of heart failure.
However, clinical identification of congestion is challenging,
unless severe. Up to 50% of outpatients with HF who were
considered to be clinically dry had sub-clinical congestion on
ultrasound, either in the pulmonary interstitium (lung B-lines)
or in the intra-vascular space, as measured by a distended
inferior vena cava (IVC). Sub-clinical congestion was associ-
ated with a poor outcome [49, 50]. Whether treatment guided
by ultrasound assessments is feasible and effective for the
management of congestion in patients with HF is currently
being explored in several small- to medium-sized trials.
Biomarker-guided management of congestion has met with
mixed success, largely because treatment was similarly effec-
tive in each arm [51]. A large trial (GUIDE-HF;
NCT03387813) is currently investigating whether pulmonary
artery pressure monitoring using a small implanted device can
help guide treatment of congestion.
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Torasemide, acetazolamide and other diuretics
Loop diuretics are the most potent diuretic agents, and furo-
semide is the most widely used in patients with HF. However,
other loop diuretics, such as bumetanide and torasemide, are
either better absorbed or delivered more reliably to the renal
tubule. Meta-analysis of small randomised trials and observa-
tional studies suggests that torasemide might be superior to
furosemide, but no substantial randomised trial has yet com-
pared these two agents [52–54]. TRANSFORM-HF
(NCT03296813) is an ongoing, multi-centre, unblinded, trial
that will randomise, prior to discharge, ~ 6000 patients admit-
ted with decompensated heart failure to long-term treatment
with oral torasemide or furosemide to investigate effects on
morbidity and mortality.
Other options for treating resistant congestion in patients
HF exist, such as combining different classes of diuretics, but
their safety and efficacy have been rarely tested in clinical
trials [55]. Most of the sodium filtered by kidneys is
reabsorbed in the proximal tubule of the nephron.
Acetazolamide, a carbonic anhydrase inhibitor, should de-
crease the amount of sodium reabsorbed in the proximal neph-
ron and enhance the distal effects of loop diuretics. The
Acetazolamide in Decompensated heart failure with Volume
OveRload (ADVOR) is a randomised, double-blind, placebo-
controlled trial which will test whether combining acetazol-
amide with a loop diuretic is more successful in achieving
decongestion in ~ 500 patients admitted with HF and signs
of fluid overload [56].
Sodium glucose co-transporter 2 inhibitors
Although not everyone would agree that it is the principal
mechanism of action of sodium glucose co-transporter 2 in-
hibitors (SGLT2i), there is little doubt that diuresis contributes
to their effects in HF. SGLT2i reduce glucose reabsorption in
the proximal nephron, increasing delivery of glucose and so-
dium to the distal nephron and inducing an osmotic diuresis.
Whether SGLT2i have additional metabolic effects on the
heart and kidney by inhibiting carbonic anhydrase or increas-
ing the availability of ketones as a metabolic substrate for the
myocardium is uncertain [57]. Empagliflozin reduced all-
cause mortality and hospitalisation for heart failure in patients
with type 2 diabetes mellitus (T2DM) and ischaemic heart
disease (IHD) [58]. Trials of canagliflozin and dapagliflozin
also suggested a reduction in hospitalisations for HF [59–61];
although the relative risk reduction was substantial, the abso-
lute benefits were very small, creating uncertainty about
whether they are clinically meaningful. Interestingly, the pro-
gramme of phase III trials for HF has not required patients to
have T2DM and has enrolled a broad range of patients with
HFrEF and HFpEF as well as in-patients and out-patients. The
first of these trials is likely to report in 2019 (DAPA-HF) [62].
Intravenous iron
Up to 50% of patients with HF have iron deficiency (ID), with
or without anaemia. ID is associated with adverse outcomes,
even in the absence of anaemia, and is a potential target of
treatment [63]. Oral iron is widely available and cheap but
only a small amount of oral iron can be absorbed in a day
(perhaps 2–10 mg/day compared with a total deficiency of
> 1,000 mg) and many patients have GI intolerance to oral
iron. Oral iron absorption may be impaired in heart failure,
possibly due to increased secretion of hepatic hepcidin, but
even if it is not, oral supplementation would take many
months to correct iron deficiency [64]. Modern preparations
of IV iron are safe and well tolerated and improve symptoms
and exercise capacity in patients with HFrEF. An individual
patient meta-analysis from four randomised controlled trials
including 839 patients with HFrEF and ID, of whom 504 were
randomised to IV ferric carboxymaltose, suggests that short-
term (mean follow-up 31 weeks) treatment could also reduce
HF hospitalisations when compared with placebo. However,
the analysis included very few cardiovascular (n = 34) or other
(n = 4) deaths and does not prove long-term safety [65]. Four
substantial (> 1000 patients) randomised trials are currently
investigating whether different formulations of IV iron (either
iron isomaltoside or ferric carboxymaltose) improve morbid-
ity and mortality in patients with chronic or acute HF. These
trials have included far more patients and recorded far more
events than the published evidence but have not yet been
stopped for benefit. Phase II trials are also investigating the
potential benefits of IV iron on symptoms, exercise tolerance
and quality of life of patients with HFpEF and ID
(NCT03074591).
Copper, selenium and co-enzyme Q10
Heart failure may be accompanied by high plasma copper
concentrations but myocardial copper depletion. There is ev-
idence from both animal models and a limited amount of
human data that copper chelation may be beneficial [66].
However, an alternative view is that low doses of the chelating
agent trientine might facilitate copper redistribution to tissues.
This concept is currently being tested in a 200-patient, dose-
ranging trial (NCT03875183).
Co-enzyme Q10 is an essential component of the mito-
chondrial electron transport chain and both co-enzyme Q10
and selenium have an important role in many metabolic pro-
cesses. Lower plasma concentrations of Q10 and selenium
have been associated with adverse outcomes in heart failure
[67–69]. Two trials showed a reduction in mortality with co-
enzyme Q10 supplements for patients with or at high-risk of
heart failure and a broad range of LVEF [70, 71]. Randomised
controlled trials are underway.
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Other trials
Pulmonary hypertension and right ventricular
dysfunction
Pulmonary hypertension (PHT) is common, especially in pa-
tients with advanced heart failure, due to a combination of left
atrial hypertension, pulmonary arteriolar hypertrophy and pul-
monary vasoconstriction. Small trials have shown that silden-
afil, a selective inhibitor of type 5 phosphodiesterase, might
improve haemodynamics and exercise performance in pa-
tients with HFrEF and PHT; other trials should report soon
[72]. In HFpEF, sildenafil was not beneficial [73]. The effects
of treprostinil, a synthetic analogue of prostacyclin with potent
vasodilator properties, on exercise capacity and NT-proBNP
are currently under investigation in a trial (n ~ 300) of HFpEF
and PHT. However, trials in patients with HFrEF were
stopped for harm. The safety, and effect on NT-proBNP levels
of macitentan, an antagonist/blocker of endothelin receptors,
will be also studied in 300 patients with HFpEF complicated
by PHT or right ventricular dysfunction (SERENADE,
NCT03153111).
Amyloidosis
Accumulation of wild-type or variant transthyretin amyloid
occurs when fibrils become unstable and misfold. Recent re-
ports suggest that 15–20% of patients with HFpEF may have
TTR amyloidosis. These patients have a poor outcome and
may not respond to conventional treatments [74]. A recent
trial showed that treatment with tafamidis, which binds to
transthyretin, preventing tetramer dissociation and
amyloidogenesis, improves symptoms, quality of life and ex-
ercise capacity and reduces cardiovascular hospitalisations
and mortality in patients with transthyretin amyloid cardiomy-
opathy [75]. The costs of tafamidis are currently prohibitive,
preventing large-scale uptake. However, demonstration of the
effectiveness of treatment will lead to changes in diagnostic
pathways (at least to identify patients who may not benefit
from some treatments or for selection into clinical trial even
if treatment is unaffordable). In due course, the cost of
tafamidis will fall.
Influenza vaccination
Influenza might be an important precipitant of HF
hospitalisations [76]. A recent observational study from
Denmark suggested that influenza vaccination might be asso-
ciated with better outcomes in patients with heart failure, but it
also reported that a large proportion (> 40%) of patients with
heart failure do not receive influenza vaccination, whichmight
reflect lack of evidence arising from trials and therefore weak
recommendations from guidelines [77]. Two large trials
investigating the ability of influenza vaccinations to reduce
morbidity and mortality should report in the next few years.
The Influenza Vaccine To Prevent Adverse Vascular Events
(RCT-IVVE) will randomise ~ 5,000 patients with HF global-
ly. The INfluenza Vaccine to Effectively Stop Cardio Thoracic
Events and Decompensated Heart Failure (INVESTED) will
compare high-dose trivalent influenza vaccine vs standard-
dose quadrivalent influenza vaccine in almost 10,000 patients
with a recent myocardial infarction or hospitalisation for HF.
Conclusions
Over the last 30 years, various pathways leading to the devel-
opment and progression of heart failure have been identified
and successfully targeted with effective therapies. This has
improved the quality of life and survival for millions of indi-
viduals with HFrEF, globally. Hopefully, new treatments will
offer further improvements and extend these successes to the
treatment of HFpEF and other specific causes and phenotypes
of HF. New concepts of how HF should be defined combined
with new analytical approaches using large data-sets will re-
shape its epidemiology and offer new therapeutic targets.
However, old age rather than cardiac dysfunction may be the
next great barrier to overcome.
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